On September 3, AKESO rose 5.3% in regular trading, trading at HK$92.5/share, with turnover of HK$107 million.

The movement was driven by the company's announcement that its proprietary PD-1/VEGF bispecific antibody ivonescimab achieved a key secondary endpoint of overall survival in the pre-specified interim analysis of the Phase 3 HARMONi-2 study. The trial evaluated ivonescimab monotherapy versus pembrolizumab monotherapy as first-line treatment for PD-L1-positive locally advanced or metastatic non-small cell lung cancer, enrolling 398 subjects. The Independent Data Monitoring Committee confirmed the OS result was both statistically significant and clinically meaningful.

This milestone follows a series of recent catalysts for AKESO. In late August, ivonescimab achieved a positive OS result in the HARMONi-GI1 Phase 3 trial for first-line biliary tract cancer, head-to-head defeating durvalumab. Earlier in August, ivonescimab received NMPA approval for its third indication — first-line treatment of squamous NSCLC. Multiple brokerages, including Guojin Securities and Guosen Securities, have maintained Buy or Outperform ratings, citing accelerating commercial momentum across core products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)